VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity and safety of the combination of
vinorelbine, carboplatin and trastuzumab in HER2-positive metastatic breast cancer.